We also demonstrated that GLV-1 h153 is effective and safe in treating SAR302503 gastric tumors in a murine xenograft model. The GLV-1 h153-treated group was continuously followed until day 35 and there was no tumor regrowth (data not shown between day 28 and 35). The control group had to be sacrificed in accordance to our approved animal protocol on day 28. Expressing the hNIS gene in an otherwise non-hNIS-expressing STA-9090 tissue is exciting. It could potentially make use of the well-established radioiodine imaging and therapy in other non-thyroid
originated cancers. Several studies have shown promising results in a variety of tumors using radioiodine treatment via tumor-specific expression of the hNIS gene, including medullary thyroid carcinoma [24], prostate cancer [25], colon cancer [26], and breast cancer [27]. Tumor-specific hNIS expression using GLV-1 h153 can maximize localized radioiodine accumulation and minimize non-specific uptake in other organs. Based on our promising results, it would be of significant clinical importance
to evaluate the effect of combination therapy of GLV-1 h153 and radioiodine. Conclusion This study demonstrates a novel oncolytic VACV engineered to express the hNIS can effectively infect, selleckchem replicate within, and cause regression of gastric cancer in a murine xenograft model. GFP expression can serve as a surrogate of viral infectivity. In vivo, GLV-1 h153 infected cells can be readily imaged with 99mTc scintigraphy and 124I PET imaging. These data provide further support for future investigation of GLV-1 h153 as a treatment else agent and a non-invasive imaging tool in the clinical settings. Acknowledgements
Technical services provided by the MSKCC Small-Animal Imaging Core Facility, supported in part by NIH Small-Animal Imaging Research Program (SAIRP) Grant No R24 CA83084 and NIH Center Grant No P30 CA08748, are gratefully acknowledged. References 1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74–108.PubMedCrossRef 2. Wanebo HJ, Kennedy BJ, Chmiel J, Steele G Jr, Winchester D, Osteen R: Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg 1993, 218:583–592.PubMedCrossRef 3. Nakajima T: Gastric cancer treatment guidelines in Japan. Gastric Cancer 2002, 5:1–5.PubMedCrossRef 4. Park CH, Song KY, Kim SN: Treatment results for gastric cancer surgery: 12 years’ experience at a single institute in Korea. Eur J Surg Oncol 2008, 34:36–41.PubMedCrossRef 5. Tsunemitsu Y, Kagawa S, Tokunaga N, Otani S, Umeoka T, Roth JA, Fang B, Tanaka N, Fujiwara T: Molecular therapy for peritoneal dissemination of xenotransplanted human MKN-45 gastric cancer cells with adenovirus mediated Bax gene transfer. Gut 2004, 53:554–560.PubMedCrossRef 6.